Viking Therapeutics, Inc. (VKTX) Financials

VKTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 608.2 million 106.3 million
Dec. 31, 2025 715.7 million 76.7 million
Sept. 30, 2025 739.4 million 26.4 million
June 30, 2025 827.9 million 32.4 million

VKTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -114.0 million 10.3 million
Dec. 31, 2025 -85.3 million 8.6 million
Sept. 30, 2025 -94.0 million 7.3 million
June 30, 2025 -47.1 million 13.5 million

VKTX Net Income

No data available :(

VKTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 603.0 million - -
Dec. 31, 2025 705.7 million - 137000
Sept. 30, 2025 714.6 million - 755000
June 30, 2025 807.7 million - 878000

VKTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 115.6 million
Dec. 31, 2025 114.0 million
Sept. 30, 2025 112.3 million
June 30, 2025 112.1 million

VKTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 150.2 million 14.0 million -
Dec. 31, 2025 - 153.5 million 11.3 million -
Sept. 30, 2025 - 90.0 million 8.6 million -
June 30, 2025 - 60.2 million 14.4 million -

VKTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - 94000
Sept. 30, 2025 - 114000
June 30, 2025 - 112000

VKTX

Price: $29.33

52 week price:
22.96
43.15

Earnings Per Share: -4.15 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.7 million

Ebitda: -4.7 million

Market Capitalization: 3.7 billion

Links: